- Home
- EXEL vs PSO Comparison
EXEL vs PSO Comparison
Compare EXEL & PSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- PSO
- Stock Information
- Founded
- EXEL 1994
- PSO 1844
- Country
- EXEL United States
- PSO United Kingdom
- Employees
- EXEL N/A
- PSO N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- PSO Books
- Sector
- EXEL Health Care
- PSO Consumer Discretionary
- Exchange
- EXEL Nasdaq
- PSO Nasdaq
- Market Cap
- EXEL 10.4B
- PSO 9.5B
- IPO Year
- EXEL 2000
- PSO 2000
- Fundamental
- Price
- EXEL $38.12
- PSO $13.74
- Analyst Decision
- EXEL Buy
- PSO
- Analyst Count
- EXEL 23
- PSO 0
- Target Price
- EXEL $44.10
- PSO N/A
- AVG Volume (30 Days)
- EXEL 3.0M
- PSO 731.8K
- Earning Date
- EXEL 11-04-2025
- PSO 01-01-0001
- Dividend Yield
- EXEL N/A
- PSO 2.38%
- EPS Growth
- EXEL 81.76
- PSO 31.65
- EPS
- EXEL 2.08
- PSO 0.90
- Revenue
- EXEL $2,230,005,000.00
- PSO $4,822,578,436.00
- Revenue This Year
- EXEL $9.14
- PSO $2.31
- Revenue Next Year
- EXEL $12.51
- PSO $4.76
- P/E Ratio
- EXEL $18.32
- PSO $15.33
- Revenue Growth
- EXEL 10.73
- PSO N/A
- 52 Week Low
- EXEL $31.90
- PSO $13.72
- 52 Week High
- EXEL $49.62
- PSO $17.90
- Technical
- Relative Strength Index (RSI)
- EXEL 46.88
- PSO 35.45
- Support Level
- EXEL $33.76
- PSO $14.78
- Resistance Level
- EXEL $40.63
- PSO $15.06
- Average True Range (ATR)
- EXEL 1.31
- PSO 0.21
- MACD
- EXEL 0.07
- PSO -0.11
- Stochastic Oscillator
- EXEL 63.54
- PSO 1.30
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About PSO Pearson Plc
Pearson PLC listed in the U.K., is an educational provider. The company has been divesting non-core businesses such as the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider. While Pearson's primary activity centers on higher education, the firm also operates in providing clinical assessments, professional certification, and testing.